Twenty-eight barrows were used to investigate the effects of exogenous porcine growth hormone (pGH) administration (0 and 100 ~tg.kg-l.d -1) between 30 and 60 kg on the subsequent and overall performance and carcass composition of pigs grown to 90 kg. The pGH was administered by daily i.m. injection and all pigs were fed one diet. Control animals were pair-fed to the intake noted for pGH-treated pigs between 30 and 60 kg and all pigs were fed ad libitum from 60 to 90 kg. Pigs administered pGH had an improved rate (36%) and efficiency (28%) of gain and an improved protein accretion rate (46%) compared to excipient-treated pigs. Pigs previously treated with pGH continued to exhibit superior (P < .01) rate and efficiency of gain, and the gain was associated with enhanced protein accretion during the quiescent (postinjection) period compared with excipient counterparts. Administration of pGH between 30 and 60 kg reduced carcass fat and increased carcass protein and water at 90 kg, although fat accretion rate was comparable to that of control pigs. Results indicate that, to varying degrees, the stimulatory effects of pGH on growth performance are sustained following cessation of hormone treatment.
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Received June 8, 1988 . Accepted October 20, 1988 growth and development between 25 and 105 kg elicits marked changes in protein and lipid metabolism resulting in enhanced growth performance and reduced carcass and body fat content (Machlin, 1972; Etherton et al., 1986 Etherton et al., , 1987 Walton et al., 1986 Walton et al., , 1987 Campbell et al., 1988) . However, no information is available on the extent to which these changes in performance and body composition are maintained following withdrawal of pGH treatment.
Results from the use of a beta-adrenergic agonist have indicated that the reduction of body fat achieved by including the compound in the diet of pigs from 60 to 105 kg is lost due to compensatory fat gain following withdrawal of the compound during a period of only 7 d (Jones et al., 1985) . Recent results of Cromwell et al. (1988) suggest that treatment decompensation did not occur with a withdrawal period of 1 to 5 d. Because there is a 1265 lack of similar data for pigs chronically treated with pGH, the present experiment examined the effects of pGH administration between 30 and 60 kg on the subsequent and overall performance of pigs grown to 90 kg live weight.
Materials and Methods
Twenty-eight Duroc x Yorkshire barrows were used in the experiment. Four pigs were killed at 30 kg to provide representative information on initial carcass composition. The remaining 24 barrows were allocated equally to pGH treatment (0, ) to 60 kg live weight. Four pigs from each treatment were killed at the latter weight and the remaining eight pigs per treatment group were fed to 90 kg live weight. Pigs were individually penned in a facility maintained at 25~ Animals were weighed weekly and pGH dose was adjusted accordingly. Pigs were fed a common diet (Table 1) ; the intake of excipient-treated animals was restlicted to the average of ad libitum intake noted for pGH-treated barrows of similar live weight during the period of pGH treatment (30 to 60 kg). Thereafter, all pigs were fed ad libitum (60 to 90 kg).
The pGH was obtained from the National Pituitary Agency (USDA-pGH-B1) and was used without further purification. The dosage of pGH was adjusted according to body weight weekly, and the amount of pGH sufficient for treatment was weighed daily, solubilized (Chung et al., 1985; bicarbonate buffer, pH 9.4 , with poll at 4 mg/ml) and administered by i.m. injection into the extensor neck muscles between 0700 and 0800. Excipient pigs were injected with a comparable volume of bicarbonate buffer.
Immediately after slaughter at 60 and 90 kg live weight, selected organs were removed and weighed. The contents of the gastrointestinal tract were removed and the empty tract was weighed. The carcass was hung overnight at 4~ The eviscerated carcass was split longitudinally and the right side was prepared for chemical analyses (Campbell et al., 1984) . The left side of the carcass was used for standard carcass measurements (Campbell et al., 1988) . Data were analyzed by one-way analysis of variance within live weight period (i.e., treated = 30 to 60 kg; withdrawal = 60 to 90 kg; overall = 30 to 90 kg) using standard procedures (SAS, 1982) .
Results
All pigs remained in good health over the active treatment period, 30 to 60 kg live weight. Between 60 and 90 kg live weight, two pigs were removed from treatment due to problems unrelated to treatment (rectal prolapse and chronic leg injury). Both pigs were from the excipient-treated group. Data for these animals were omitted in calculation of the withdrawal and overall treatment period results.
Between 30 and 60 kg, pigs treated with pGH had faster and more efficient gain (P < .01) than their excipient-treated counterparts (Table 2 ). Pigs treated with pGH from 30 to 60 kg consumed less feed and exhibited faster and more efficient growth (P < .01) from 60 to 90 kg, and subsequently (P < .01) for the overall period (30 to 90 kg), compared with barrows treated with excipient buffer between 30 and 60 kg live weight.
Carcasses of pGH-treated pigs contained less fat (P < .01) and more water (P < .01) and protein (P < .05) at 60 kg and more water and less fat (P < .05) at 90 kg compared with excipient-treated pigs (Table 3) . Differences in carcass fat content were generally reflected in the linear carcass fat measurements at both 60 and 90 kg (Table 4) , although the treatment means for carcass fat measured over the longissimus muscle at the Pl, P2 and P3 (fat thickness measured at 40, 60 and 100 mm, respectively, from the midline at the level of the last rib) positions were different (P < .05) only at 90 kg live weight. Administration of pGH increased (P < .05) longissimus muscle area at 60 and 90 kg and carcass length at 60 (Table  4) . Accretion rates for chemical components of the eviscerated carcass for the three live weight periods are shown in Table 5 . Administration of pGH between 30 and 60 kg increased the accretion rates for water, protein and ash for each of the three live weight periods designated and decreased the accretion rate of carcass fat deposition between 30 and 60 kg. The ratio of fat:protein in carcass gain was reduced in all periods by pGH administration between 30 and 60 kg (Table 5) .
Treatment effects on selected organ weights assessed at 60 and 90 kg are shown in Table 6 . Heart and kidney weights were increased at 60 kg by pGH administration, and the effect on kidney weight was still evident at 90 kg live weight. 
Discussion
The increases in growth performance and changes in carcass composition at 60 kg body weight elicited by pGH administration in the present study were similar in magnitude to those reported previously for pigs of slightly lighter weight (Campbell et al., 1988) and comparable with the results of Boyd et al. (1986) and Etherton et al. (1986 Etherton et al. ( , 1987 for pigs weighing 55 to 105 kg. Cumulative results from these studies indicate that the pig is responsive to pGH administration during much of the postnatal development period.
The 36% faster growth rate and 28% lower feed:gain ratio due to pGH treatment during the active treatment period from 30 to 60 kg live weight was related to the increased protein (46%) and water (62%) deposition rates. These findings are consistent with results from a previous study (Campbell et al., 1988) and suggest that pGH acts either directly or via somatomedins to stimulate protein accretion by muscle tissue. These results suggest further that this action on muscle tissue is, in part, the mechanism underlying GH improvement of growth performance.
The reduction of carcass fat at 60 kg as induced by pGH was associated with a marked reduction in the fat:protein ratio, which was related in turn to the enhancement of protein accretion and reduction of fat deposition. Again, these data are consistent with the results of Boyd et al. (1986) , Etherton et al. (1986 Etherton et al. ( , 1987 and Campbell et al. (1988) .
The present results showed, however, that the effects of pGH on growth performance and body composition were sustained following cessation of treatment at 60 kg. The improved performance between 60 and 90 kg of pigs previously treated with pGH was associated with enhanced protein and water deposition compared with excipient-treated control pigs. The improvements in growth rate, feed:gain ratio and protein accretion exhibited subsequent to 60 kg by pGH-treated pigs were of lesser magnitude than those exhibited during the active treatment phase and considerably below those values as calculated from the results of Boyd et al. (1986) and Etherton et al. (1986 Etherton et al. ( , 1987 for the pigs treated with pGH continuously from 55 to 105 kg. Nevertheless, growth performance and protein accretion were greater (P < .01) than in excipient-treated ~c~. control pigs and resulted in improved overall performance. The differences in carcass fat content and carcass fat measurements resulting from pGH treatment from 30 to 60 kg were still evident and slightly enhanced at 90 kg (Tables 3 and  4) . These results are in contrast to those of Jones et al. (1985) , who reported that withdrawal of beta-agonist treatment from the diet of pigs resulted in immediate compensatory fat deposition and increases in carcass fat measurements toward control values. This difference between pGH and beta-agonist effects is not surprising, because beta-adrenergic drugs have a smaller effect on carcass fat content than does pGH, and the two strategies to manipulate growth performance and composition exert their effects through separate mechanisms (Beerman et al., 1986) . Jones et al. (1985) also reported that voluntary feed intake of pigs treated with beta-adrenergic agonist overcompensated upon withdrawal of the drug from the diet. In the present experiment, voluntary feed intake of pigs treated with pGH subsequent to 60 kg remained depressed (Table 2 ). This result is consistent with the greater lean body mass of pGH-treated pigs and maintenance of accelerated protein accretion. High levels of feed intake during the finishing phase of growth (60 to 90 kg) are associated with accelerated fat deposition and a deterioration of feed:gain ratio (Campbell and Taverner, 1985) .
Evidence in rats suggests that GH via somatomedins stimulates satellite cell proliferation and recruitment into primary muscle cell fibers (Dodson et al., 1985) . Although speculative, similar effects in the present experiment may explain the sustained response on protein accretion following withdrawal of treatment. In both the pig (Campbell and Dunkin, 1983) and chicken (Hentges et al., 1983) , capacity for protein deposition is correlated positively with the number of muscle nuclei.
Another explanation for the results of the present experiment is that the greater protein accretion rate exhibited between 60 and 90 kg was a result of the pGH-treated pigs' being physiologically younger at 60 kg, and, as such, they had a greater capacity for muscle growth. According to the results of Shields et al. (1983) , this effect is synonymous with the assessment of protein accretion rates in animals that differ approximately 15 d in age at the transitory point of the growth curve for lean body mass. Clearly, further research is required to elucidate the precise mechanism that underlies the pGH effect on protein accretion and explain this sustained benefit in growth performance and body composition following withdrawal of pGH treatment. 
